The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Abstract
OBJECTIVE: Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia. This review evaluates evidence from preclinical and clinical studies that brain glutamatergic neurotransmission is altered in schizophrenia, may affect symptom expression, and is modulated by antipsychotic drugs. METHOD: A comprehensive review of scientific articles published over the last decade that address the role of glutamate in the pathophysiology of schizophrenia was carried out. RESULTS: Glutamatergic neurons are the major excitatory pathways linking the cortex, limbic system, and thalamus, regions that have been implicated in schizophrenia. Postmortem studies have revealed alterations in pre- and postsynaptic markers for glutamatergic neurons in several brain regions in schizophrenia. The N-methyl-D-aspartic acid (NMDA) subtype of glutamate receptor may be particularly important as blockade of this receptor by the dissociative anesthetics reproduces in normal subjects the symptomatic manifestations of schizophrenia, including negative symptoms and cognitive impairments, and increases dopamine release in the mesolimbic system. Agents that indirectly enhance NMDA receptor function via the glycine modulatory site reduce negative symptoms and variably improve cognitive functioning in schizophrenic subjects receiving typical antipsychotics. CONCLUSIONS: Dysfunction of glutamatergic neurotransmission may play an important role in the pathophysiology of schizophrenia, especially of the negative symptoms and cognitive impairments associated with the disorder, and is a promising target for drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566 · cited 1×
“Long-term potentiation has been linked to memory formation (24).”
BackgroundGlutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“implications of activity in this complex model unclear (104).”
BackgroundMcDonald, J. W., & Johnston, M. V. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90011-c · Cited by 1,416
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
Cited by
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
“It has been postulated that the mesolimbic dopamine abnormality may be a primary neurochemical abnormality (3, 6), a secondary consequence of hypofrontality (1, 156), secondary to a glutamate deficit (33, 157, 158), or secondary to a primary neurodevelopmental disorder (159–161).”
Neuregulin 1 and Susceptibility to Schizophrenia
Stefansson, H., Petursson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,683
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
“This may have particular relevance in schizophrenia, as glutamatergic dysfunction has been implicated as a pathophysiological pathway (Goff and Coyle, 2001).”
BackgroundMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
The Computational Anatomy of Psychosis
Adams, R. A., Stephan, K. E., Brown, H. R., Frith, C. D., & Friston, K. J. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00047 · Cited by 850
“NMDA-Rs play a central role in theories of schizophrenia (Olney and Farber, 1995; Abi-Saab et al., 1998; Goff and Coyle, 2001; Stephan et al., 2006; Corlett et al., 2011).”
BackgroundStructural dynamics of dendritic spines in memory and cognition
Kasai, H., Fukuda, M., Watanabe, S., Hayashi-Takagi, A., & Noguchi, J. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.01.001 · Cited by 804
Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report
Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M., Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown, R. A., George, T. P., Williams, J., et al. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802443569 · Cited by 735
Zheng, P., Zeng, B., Liu, M., Chen, J., Pan, J., Han, Y., Liu, Y., Cheng, K., Zhou, C., Wang, H., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau8317 · Cited by 704
The environment and susceptibility to schizophrenia
Brown, A. S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.003 · Cited by 664
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Increased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 609
Schizophrenia: Diverse Approaches to a Complex Disease
Sawa, A., & Snyder, S. H. (2002) · Science · doi:10.1126/science.1070532 · Cited by 597
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Self-citationAugmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 490
Disrupted prediction-error signal in psychosis: Evidence for an associative account of delusions
Corlett, P. R., Murray, G. K., Honey, G. D., Aitken, M. R. F., Shanks, D. R., Robbins, T. W., Bullmore, E. T., Dickinson, A., & Fletcher, P. C. (2007) · Brain · doi:10.1093/brain/awm173 · Cited by 460
Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia
Phillips, W. A., & Silverstein, S. M. (2003) · Behavioral and Brain Sciences · doi:10.1017/s0140525x03000025 · Cited by 445
“Many reviews of PCP-psychosis and the associated glutamatergic hypothesis of schizophrenia are available (Coyle 1996; Ellison 1995; Goff & Coyle 2001; Javitt & Zukin 1991; Jentsch & Roth 1999; Olney & Farber 1995; Olney et al. 1999; Tamminga 1998).”
BackgroundJackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Self-citationGlutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Woo, T.-U. W., Walsh, J. P., & Benes, F. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.649 · Cited by 411
NMDA Receptor and Schizophrenia: A Brief History
Coyle, J. T. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs076 · Cited by 410
Self-citationDisrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1
Hayashi-Takagi, A., Takaki, M., Graziane, N., Seshadri, S., Murdoch, H., Dunlop, A. J., Makino, Y., Seshadri, A. J., Ishizuka, K., Srivastava, D. P., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2487 · Cited by 399
Loftis, J. M., & Janowsky, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00302-9 · Cited by 362
Dopamine Partial Agonists: A New Class of Antipsychotic
Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340
Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia
Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G., & Grecksch, G. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00080-0 · Cited by 339
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia
Takahashi, N., Sakurai, T., Davis, K. L., & Buxbaum, J. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.004 · Cited by 337
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
Psychosis pathways converge via D2High dopamine receptors
Seeman, P., Schwarz, J., Chen, J.-F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 330
Modeling madness in mice: one piece at a time
Arguello, P. A., & Gogos, J. A. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.023 · Cited by 309
d‐Amino acids in the brain:d‐serine in neurotransmission and neurodegeneration
Wolosker, H., Dumin, E., Balan, L., & Foltyn, V. N. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06515.x · Cited by 309
Schizophrenia: Etiology and Course
Walker, E., Kestler, L., Bollini, A., & Hochman, K. M. (2004) · Annual Review of Psychology · doi:10.1146/annurev.psych.55.090902.141950 · Cited by 297
Apoptotic mechanisms and the synaptic pathology of schizophrenia
Glantz, L. A., Gilmore, J. H., Lieberman, J. A., & Jarskog, L. F. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.014 · Cited by 292
Prenatal Nutritional Deficiency and Risk of Adult Schizophrenia
Brown, A. S., & Susser, E. S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn096 · Cited by 289
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A., & Tsai, S.-J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 282
Schubert, F., Gallinat, J., Seifert, F., & Rinneberg, H. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.11.014 · Cited by 282
Schizophrenia: from phenomenology to neurobiology
Wong, A. H. C., & Van Tol, H. H. M. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00035-6 · Cited by 280
Straub, R. E., Lipska, B. K., Egan, M. F., Goldberg, T. E., Callicott, J. H., Mayhew, M. B., Vakkalanka, R. K., Kolachana, B. S., Kleinman, J. E., & Weinberger, D. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001988 · Cited by 276
Gandal, M. J., Edgar, J. C., Klook, K., & Siegel, S. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.007 · Cited by 269
Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania
Öngür, D., Jensen, J. E., Prescot, A. P., Stork, C., Lundy, M., Cohen, B. M., & Renshaw, P. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.014 · Cited by 270
Théberge, J., Al-Semaan, Y., Williamson, P. C., Menon, R. S., Neufeld, R. W. J., Rajakumar, N., Schaefer, B., Densmore, M., & Drost, D. J. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.12.2231 · Cited by 269
Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267
“Furthermore, administration with d-serine could improve cognition and decrease negative symptoms in schizophrenic patients receiving typical antipsychotics (Goff and Coyle, 2001).”
BackgroundCannon, T. D., van Erp, T. G. M., Bearden, C. E., Loewy, R., Thompson, P., Toga, A. W., Huttunnen, M. O., Keshavan, M. S., Seidman, L. J., & Tsuang, M. T. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007037 · Cited by 266
Laan, W., Grobbee, D. E., Selten, J.-P., Heijnen, C. J., Kahn, R. S., & Burger, H. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05117yel · Cited by 264
Freudenreich, O., & Goff, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 259
Self-citationHomayoun, H., Stefani, M. R., Adams, B. W., Tamagan, G. D., & Moghaddam, B. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300417 · Cited by 252
Disorders of diminished motivation
Marin, R. S., & Wilkosz, P. A. (2005) · Journal of Head Trauma Rehabilitation · doi:10.1097/00001199-200507000-00009 · Cited by 241
Bitanihirwe, B. K., Peleg-Raibstein, D., Mouttet, F., Feldon, J., & Meyer, U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.129 · Cited by 237
Pennington, K., Beasley, C. L., Dicker, P., Fagan, A., English, J., Pariante, C. M., Wait, R., Dunn, M. J., & Cotter, D. R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002098 · Cited by 227
“69 Postsynaptic density and glutamatergic system implicated by findings Several proteins that were differentially expressed in this investigation, namely PACSIN, NF-L, DYN-I and septin 5, are involved in the function of the pre- andsor postsynaptic density, and through these in NMDA-regulated glutamatergic neurotransm…”
BackgroundStone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.006 · Cited by 231
Kristiansen, L. V., Beneyto, M., Haroutunian, V, & Meador-Woodruff, J. H. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001844 · Cited by 220
Modulators in concert for cognition: Modulator interactions in the prefrontal cortex
Briand, L. A., Gritton, H., Howe, W. M., Young, D. A., & Sarter, M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.06.007 · Cited by 216
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
Moreira, F. A., & Guimarães, F. S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.040 · Cited by 206
Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
Seeman, P., Ko, F., & Tallerico, T. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001682 · Cited by 200
Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders
Pinares-Garcia, P., Stratikopoulos, M., Zagato, A., Loke, H., & Lee, J. (2018) · Brain Sciences · doi:10.3390/brainsci8080154 · Cited by 200
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Extracellular matrix abnormalities in schizophrenia
Berretta, S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.010 · Cited by 179
Duffy, S., Labrie, V., & Roder, J. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301486 · Cited by 173
“D-Serine in Psychiatric Disease Recent evidence points to NMDA-receptor hypofunction mediated by low D-serine as a specific causative factor in some behavioral endotypes of schizophrenia (Mohn et al, 1999; Goff and Coyle, 2001; Chumakov et al, 2002).”
BackgroundExtinction memory is impaired in schizophrenia
Holt, D. J., Lebron-Milad, K., Milad, M. R., Rauch, S. L., Pitman, R. K., Orr, S. P., Cassidy, B. S., Walsh, J. P., & Goff, D. C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.017 · Cited by 170
Kinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.016 · Cited by 169
Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment
Chapman, M. R., & Vause, H. E. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020181 · Cited by 167
“produce symptoms of schizophrenia (12).”
A Dynamical Systems Hypothesis of Schizophrenia
Loh, M., Rolls, E. T., & Deco, G. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030228 · Cited by 164
“The proposed mechanism links the cognitive and negative symptoms of schizophrenia in an attractor framework and is consistent with a close relation between the cognitive and negative symptoms: blockade of NMDA receptors by dissociative anesthetics such as ketamine produces in healthy subjects schizophrenic symptoms, i…”
BackgroundNeural basis of psychosis-related behaviour in the infection model of schizophrenia
Meyer, U., & Feldon, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.022 · Cited by 158
Çetin, M. S., Christensen, F., Abbott, C. C., Stephen, J. M., Mayer, A. R., Cañive, J. M., Bustillo, J. R., Pearlson, G. D., & Calhoun, V. D. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.04.009 · Cited by 154
Gupta, D. S., McCullumsmith, R. E., Beneyto, M., Haroutunian, V., Davis, K. L., & Meador‐Woodruff, J. H. (2005) · Synapse · doi:10.1002/syn.20164 · Cited by 146
Murphy, E. R., Dalley, J. W., & Robbins, T. W. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2068-3 · Cited by 145
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144
“Introduction tasks (Quartermain et al.,1994), and visual recognitionmemory Converging lines of evidence have implicated dysregulation of N-methyl D-aspartate (NMDA) receptors as a factor contributing to clinical and cognitive features of schizophrenia (Goff and Coyle, 2001).”
Self-citationLiu, Y., Ouyang, P., Zheng, Y., Mi, L., Zhao, J., Ning, Y., & Guo, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.664535 · Cited by 129
Failure of Neural Responses to Safety Cues in Schizophrenia
Holt, D. J., Coombs, G., Zeidan, M. A., Goff, D. C., & Milad, M. R. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2310 · Cited by 121
Self-citationMechanisms of Working Memory Impairment in Schizophrenia
Van Snellenberg, J. X., Girgis, R. R., Horga, G., van de Giessen, E., Slifstein, M., Ojeil, N., Weinstein, J. J., Moore, H., Lieberman, J. A., Shohamy, D., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.02.017 · Cited by 123
Transcranial magnetic stimulation: A neuroscientific probe of cortical function in schizophrenia
McClintock, S. M., Freitas, C., Oberman, L., Lisanby, S. H., & Pascual-Leone, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.031 · Cited by 101
Gamma oscillation deficits and the onset and early progression of schizophrenia
Woo, T.-U. W., Spencer, K., & McCarley, R. W. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747609 · Cited by 96
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
Kondziella, D., Brenner, E., Eyjolfsson, E. M., & Sonnewald, U. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.09.006 · Cited by 83
Ranlund, S., Adams, R. A., Díez, Á., Constante, M., Dutt, A., Hall, M., Maestro Carbayo, A., McDonald, C., Petrella, S., Schulze, K., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23035 · Cited by 77
“…in those with a genetic risk for psychosis— as well as an additional reduction in patients with psychosis compared to relatives—is in line with theories of NMDA-R hypofunction in psychosis [Abi-Saab et al., 1998; Corlett et al., 2011; Goff and Coyle, 2001; Olney et al., 1999; Stephan et al., 2006].”
ResultD-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
Gottlieb, J. D., Cather, C., Shanahan, M., Creedon, T., Macklin, E. A., & Goff, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.029 · Cited by 73
“Converging evidence has linked hypofunction of glutamatergic N-methyl D-aspartate (NMDA) receptors to both cognitive deficits and psychotic symptoms in schizophrenia (Goff and Coyle, 2001).”
BackgroundSelf-citationThe potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Self-citationParadis, É., Clavel, S., Julien, P., Murthy, M. R. V., de Bilbao, F., Arsenijevic, D., Giannakopoulos, P., Vallet, P., & Richard, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.017 · Cited by 67
Behavioral and molecular evidence for psychotropic effects in l-theanine
Wakabayashi, C., Numakawa, T., Ninomiya, M., Chiba, S., & Kunugi, H. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2440-z · Cited by 65
“The NMDA receptor hypofunction hypothesis of schizophrenia suggests that increase in the NMDA receptor function via pharmacological manipulation could provide a potential new strategy for the management of schizophrenia (Goff and Coyle 2001; Javitt and Zukin 1991).”
BackgroundFaccidomo, S., Bannai, M., & Miczek, K. A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.7 · Cited by 62
Onwordi, E. C., Whitehurst, T., Mansur, A., Statton, B., Berry, A., Quinlan, M., O’Regan, D. P., Rogdaki, M., Marques, T. R., Rabiner, E. A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01515-3 · Cited by 55
Calcagno, E., Carli, M., & Invernizzi, R. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03600.x · Cited by 54
Otto, M. W., Basden, S. L., Leyro, T. M., McHugh, R. K., & Hofmann, S. G. (2007) · CNS Spectrums · doi:10.1017/s1092852900020526 · Cited by 53
Dauvermann, M. R., Whalley, H. C., Romaniuk, L., Valton, V., Owens, D. G. C., Johnstone, E. C., Lawrie, S. M., & Moorhead, T. W. J. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.01.063 · Cited by 49
“This suggests that glutamate neurotransmission, specifically NMDA receptor-mediated transmission, may be disrupted in schizophrenia (Goff and Coyle, 2001; Goff et al., 1995; Javitt et al., 1994; Moghaddam et al., 1997).”
BackgroundWang, X., Pinto-Duarte, A., Sejnowski, T. J., & Behrens, M. M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4907 · Cited by 46
“The hypo-NMDA hypothesis of schizophrenia (70, 94, 177) predicted electrophysiological consequences of acute and chronic noncompetitive NMDAR blockade, providing insights into distinct circuit mechanisms that contribute to the schizophrenic brain.”
Neurochemical evidence for differential effects of acute and repeated oxytocin administration
Benner, S., Aoki, Y., Watanabe, T., Endo, N., Abe, O., Kuroda, M., Kuwabara, H., Kawakubo, Y., Takao, H., Kunimatsu, A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-018-0249-4 · Cited by 40
Recent advances in psychoneuroimmunology: Inflammation in psychiatric disorders
Debnath, M., Doyle, K., Langan, C., McDonald, C., Leonard, B., & Cannon, D. (2011) · Translational Neuroscience · doi:10.2478/s13380-011-0019-0 · Cited by 28
Sinha, S., Patro, N., Tiwari, P. K., & Patro, I. K. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104877 · Cited by 28
Smesny, S., Langbein, K., Rzanny, R., Gussew, A., Burmeister, H. P., Reichenbach, J. R., & Sauer, H. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.031 · Cited by 18
Sociability development in mice with cell-specific deletion of the NMDA receptor NR1 subunit gene
Ferri, S. L., Pallathra, A. A., Kim, H., Dow, H. C., Raje, P., McMullen, M., Bilker, W. B., Siegel, S. J., Abel, T., & Brodkin, E. S. (2020) · Genes, Brain and Behavior · doi:10.1111/gbb.12624 · Cited by 15
Addressing altered anticipation as a transdiagnostic target through computational psychiatry
Sepúlveda, P., Aitsahalia, I., Kumar, K., Atkin, T., & Iigaya, K. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.02.014 · Cited by 3
Metadata
- Authors
- Goff, D. C., & Coyle, J. T.
- Venue
- American Journal of Psychiatry
- Published
- 2001-09-01
- Volume
- 158
- Issue
- 9
- Pages
- 1367-1377
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2156035025
- Cited by
- 915
- References
- 147
- FWCI
- 29.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.